Sun Woo Lim
Overview
Explore the profile of Sun Woo Lim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
1259
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Cui S, Fang X, Lee H, Shin Y, Koh E, Chung S, et al.
J Transl Med
. 2023 Feb;
21(1):138.
PMID: 36814269
Objectives: To explore the possibility of kidney organoids generated using patient derived human induced pluripotent stem cells (hiPSC) for modeling of Fabry disease nephropathy (FDN). Methods: First, we generated hiPSC...
12.
Cui S, Shin Y, Fang X, Lee H, Eum S, Ko E, et al.
Transl Res
. 2023 Feb;
258:35-46.
PMID: 36805562
The objective of this study was to investigate whether CRISPR/Cas9-mediated suppression of A4GALT could rescue phenotype of Fabry disease nephropathy (FDN) using human induced pluripotent stem cells (hiPSCs) derived kidney...
13.
Lim S, Fang X, Cui S, Lee H, Shin Y, Ko E, et al.
Int J Mol Sci
. 2023 Feb;
24(3).
PMID: 36769335
The aim of this study is to explore the possibility of modeling Gitelman's disease (GIT) with human-induced pluripotent stem cell (hiPSC)-derived kidney organoids and to test whether gene correction using...
14.
Kim I, Jung W, You G, Lee H, Shin Y, Lim S, et al.
Macromol Biosci
. 2023 Feb;
23(4):e2200423.
PMID: 36728673
In this study, a novel polyhistidine-incorporated lipid nanoparticle (pHis/LNP) is developed for the delivery of therapeutic globotriaosylceramide (Gb3) synthase siRNAs using a microfluidic device with pHis as a biocompatible method...
15.
Lim S, Shin Y, Cui S, Ko E, Yoo S, Chung B, et al.
Korean J Intern Med
. 2022 Jun;
37(5):1031-1049.
PMID: 35725307
Background/aims: We previously proposed minicircle vector technology as the potential platform for the development and production of new biologics. In this study, we have designed a novel target molecule for...
16.
Ko E, Shin Y, Cui S, Lim S, Chung B, Yang C
Am J Transplant
. 2022 Mar;
22(6):1537-1549.
PMID: 35294797
Sodium/glucose co-transporter-2 inhibitor (SGLT2i) or dipeptidyl peptidase IV inhibitor (DPP4i) is a newer anti-diabetic drug in type II diabetes mellitus (DM), but their use in tacrolimus (TAC)-induced DM is still...
17.
Kim K, Shin Y, Kim B, Cui S, Ko E, Lim S, et al.
Kidney Res Clin Pract
. 2021 Nov;
40(4):698-711.
PMID: 34781643
Background: Endothelial cell (EC) dysfunction is a frequent feature in patients with end-stage renal disease (ESRD). The aim of this study was to generate human induced pluripotent stem cells, differentiate...
18.
Lim S, Woon Kim K, Kim B, Shin Y, Luo K, Quan Y, et al.
Korean J Intern Med
. 2021 Sep;
37(2):411-424.
PMID: 34521186
Background/aims: Renal ischemia followed by reperfusion (I/R) is a leading cause of acute kidney injury (AKI), which is closely associated with high morbidity and mortality. Studies have shown that induced...
19.
Shin Y, Lim S, Cui S, Ko E, Chung B, Kim H, et al.
Mol Neurobiol
. 2021 Aug;
58(11):5954-5970.
PMID: 34435330
The influence of long-term tacrolimus treatment on cognitive function remains to be elucidated. Using a murine model of chronic tacrolimus neurotoxicity, we evaluated the effects of tacrolimus on cognitive function,...
20.
Woo H, Lim S, Sohn S
PLoS One
. 2021 Aug;
16(8):e0256157.
PMID: 34407130
Subcontractors depend heavily on their prime contractor and thus find it very risky to enter a new business on their own. This study proposes a framework for these subcontractors to...